These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 18701419

  • 1. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
    Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M.
    Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
    [Abstract] [Full Text] [Related]

  • 2. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
    Harenberg J, Giese C, Hagedorn A, Traeger I, Fenyvesi T.
    Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
    [Abstract] [Full Text] [Related]

  • 3. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P, Kuitunen A, Petäjä J, Ilveskero S, Lassila R.
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [Abstract] [Full Text] [Related]

  • 4. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S, Nasimi M, Colucci M, Nenci GG, Gresele P.
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [Abstract] [Full Text] [Related]

  • 5. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications.
    Harder S, Parisius J, Picard-Willems B.
    Thromb Res; 2008 Mar; 123(2):396-403. PubMed ID: 18571698
    [Abstract] [Full Text] [Related]

  • 6. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin.
    Korte W, Jovic R, Hollenstein M, Degiacomi P, Gautschi M, Ferrández A.
    Hamostaseologie; 2010 Nov; 30(4):212-6. PubMed ID: 21057708
    [Abstract] [Full Text] [Related]

  • 7. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
    Ofosu FA, Lormeau JC, Craven S, Dewar L, Anvari N.
    Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455
    [Abstract] [Full Text] [Related]

  • 8. The PiCT® test is a reliable alternative to the activated partial thromboplastin time in unfractionated heparin therapy management: results from a multicenter study.
    Brisset AC, Ferrández A, Krause M, Rathbun S, Marlar R, Korte W.
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [Abstract] [Full Text] [Related]

  • 9. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
    Maddineni J, Hoppensteadt DA, Cornelli U, Manoni M, Fareed J.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
    [Abstract] [Full Text] [Related]

  • 10. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
    Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennett M, Horton S, Shann F, Lane G, Ross-Smith M, Monagle P.
    Thromb Res; 2007 Jan; 120(3):347-51. PubMed ID: 17118432
    [Abstract] [Full Text] [Related]

  • 11. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
    Dempfle CE, Zharkowa U, Elmas E, Ahmad-Nejad P, Neumaier M, Borggrefe M.
    Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540
    [Abstract] [Full Text] [Related]

  • 12. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
    Graff J, Picard-Willems B, Harder S.
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
    [Abstract] [Full Text] [Related]

  • 13. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J.
    J Mal Vasc; 1987 Apr; 12 Suppl B():68-70. PubMed ID: 2834495
    [Abstract] [Full Text] [Related]

  • 14. Monitoring of unfractionated heparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent (PiCT®).
    Schaden E, Jilch S, Hacker S, Schober A, Kozek-Langenecker S.
    Clin Chim Acta; 2012 Dec 24; 414():202-5. PubMed ID: 23041210
    [Abstract] [Full Text] [Related]

  • 15. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G, Heiden M, Köhler M.
    Arzneimittelforschung; 1993 May 24; 43(5):542-7. PubMed ID: 8392345
    [Abstract] [Full Text] [Related]

  • 16. Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent.
    Schaden E, Schober A, Hacker S, Spiss C, Chiari A, Kozek-Langenecker S.
    Blood Coagul Fibrinolysis; 2010 Apr 24; 21(3):256-61. PubMed ID: 20087172
    [Abstract] [Full Text] [Related]

  • 17. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J, Raschke R.
    Chest; 2004 Sep 24; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [Abstract] [Full Text] [Related]

  • 18. From heparins to factor Xa inhibitors and beyond.
    Alban S.
    Eur J Clin Invest; 2005 Mar 24; 35 Suppl 1():12-20. PubMed ID: 15701143
    [Abstract] [Full Text] [Related]

  • 19. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A, Alban S, Omer-Adam MA, Weitschies W, Warkentin TE.
    Thromb Res; 2008 Mar 24; 122(2):211-20. PubMed ID: 18262226
    [Abstract] [Full Text] [Related]

  • 20. Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay.
    Harenberg J, Haaf B, Dempfle CE, Stehle G, Heene DL.
    Nephrol Dial Transplant; 1995 Mar 24; 10(2):217-22. PubMed ID: 7753456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.